Alendronate Sodium Tablet
Product Images NDC 70518-1192

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 70518-1192). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (1203dd0c 809a 4409 B948 B5e816b8a63a 01)

FDA Label Image

2 (1203dd0c 809a 4409 B948 B5e816b8a63a 02)

This text provides information about the cumulative incidence of hip fractures in a three-year study of patients with radiographic vertebral fractures at baseline. The data compares the cumulative incidence between a placebo group and a group receiving alendronate sodium over a period of time in months.*

FDA Label Image

3 (1203dd0c 809a 4409 B948 B5e816b8a63a 03)

This text provides data on osteoporosis treatment studies in postmenopausal women focusing on the increase in Bone Mineral Density (BMD) after three years of taking Alendronate Sodium at a dosage of 10 mg per day. The study includes measurements at the Lumbar Spine, Femoral Neck, and Trochanter.*

FDA Label Image

4 (1203dd0c 809a 4409 B948 B5e816b8a63a 04)

FDA Label Image

5 (1203dd0c 809a 4409 B948 B5e816b8a63a 05)

FDA Label Image

6 (1203dd0c 809a 4409 B948 B5e816b8a63a 06)

This text describes a study focusing on the effects of Alendronate Sodium, a medication used in the treatment of osteoporosis, on bone mineral density in patients treated with glucocorticoids. The study specifically shows an increase in bone mineral density after one year of taking Alendronate Sodium at a 5 mg daily dose. The areas of measurement include the lumbar spine, femoral neck, and trochanter.*

FDA Label Image

7 (1203dd0c 809a 4409 B948 B5e816b8a63a 07)

Studies in Paget's Disease of Bone comparing the effect on Serum Alkaline Phosphatase of Alendronate Sodium 40 mg/day versus Placebo or Etidronate 400 mg/day. The study involved 27 participants with Alendronate Sodium from the US and 47 participants under Placebo or Etidronate. The graph displays Serum Alkaline Phosphatase changes over time in months.*

FDA Label Image

Remedy_label (Remedy Label)

This text provides information about a prescription medication containing Alendronate Sodium 35 mg in tablet form. The medication was manufactured by Cipla Ltd in India, with the specific lot number and expiration date specified. The directions for use recommend consulting the package insert, and storage guidelines indicate keeping the medication at temperatures between 20-25°C (58-77°F) with excursions permitted to 15.3°C (59-86°F). The medication quantity is 12 tablets and it's important to keep it out of the reach of children. Additionally, details about repackaging by Remedy Repack Inc. in Indiana are given for reference.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.